Eisai Co. vs Replimune: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Eisai Co., Ltd. (4523.JP)

Q3 202630 Jun – 25 Sep 2026

▲4

Eisai Q3: Leqembi at-home approvals and oncology wins drive growth

Leqembi at-home subcutaneous approval and launches The FDA approved at-home subcutaneous Leqembi/Iqlik, with launches in the US, plus approvals in China and Japan enabling at-home use. This expands patient access and convenience, potentially boosting sales.
This is a major new approval and launch that directly impacts Eisai's growth prospects.
Strong Leqembi sales and royalty growth Q2 Leqembi sales reached ¥29.3bn, with royalties up 43% excluding China stockpiling. This indicates robust demand and successful commercialization.
Sales and royalty figures are key financial metrics showing Leqembi's market performance.
Oncology pipeline advances UK validated taletrectinib, and the FDA approved WELIREG plus LENVIMA for advanced kidney cancer. These expand Eisai's oncology portfolio and revenue potential.
New approvals and validations in oncology represent additional growth drivers beyond Leqembi.
AI drug-discovery partnership with Nvidia Eisai joined Nvidia’s AI drug-discovery push, which could enhance future pipeline productivity and innovation.
This strategic move may improve long-term R&D efficiency and is a new development.

August 202629 Jul – 25 Sep 2026

▲5

Leqembi's Global Rollout Accelerates with New Approvals and Reimbursement

Leqembi Q2 Sales Show Strong Underlying Growth Leqembi sales hit 29.3 billion yen in Q2 2026, with royalty revenue up 43% excluding a one-time China stockpiling effect. This signals robust real demand, supporting Eisai's revenue and profit outlook.
Shows strong sales momentum, a key driver of Eisai's earnings and stock price.
FDA Approves Leqembi Autoinjector, Expanding US Access The FDA approved Leqembi Iqlik subcutaneous autoinjector for weekly initiation, with a US launch in August. This makes treatment easier and more convenient, likely boosting patient uptake and sales.
New approval expands market access and convenience, directly driving future sales.
Canada Recommends Public Reimbursement for Leqembi Canada's Drug Agency gave a final positive recommendation for public reimbursement of Leqembi. This paves the way for government-funded access, potentially increasing patient numbers and sales in Canada.
Reimbursement is crucial for uptake; this opens a new market for Eisai.
China and Japan Approve Subcutaneous Leqembi, Enabling At-Home Use China and Japan approved subcutaneous Leqembi, allowing at-home administration. This could significantly boost adoption by removing the need for hospital infusions, expanding the patient pool in two major markets.
Subcutaneous approval in key markets improves convenience and access, driving demand.
FDA Approves WELIREG Plus LENVIMA for Advanced Kidney Cancer The FDA approved the combination of WELIREG and Eisai's LENVIMA for advanced kidney cancer, based on a trial showing reduced progression risk. This adds a new revenue stream for Eisai's oncology portfolio.
New approval diversifies Eisai's revenue beyond Alzheimer's, supporting growth.

Latest29 Jul – 25 Sep 2026

▲5

Leqembi's Global Rollout Accelerates with New Approvals and Reimbursement

Leqembi Q2 Sales Show Strong Underlying Growth Leqembi sales hit 29.3 billion yen in Q2 2026, with royalty revenue up 43% excluding a one-time China stockpiling effect. This signals robust real demand, supporting Eisai's revenue and profit outlook.
Shows strong sales momentum, a key driver of Eisai's earnings and stock price.
FDA Approves Leqembi Autoinjector, Expanding US Access The FDA approved Leqembi Iqlik subcutaneous autoinjector for weekly initiation, with a US launch in August. This makes treatment easier and more convenient, likely boosting patient uptake and sales.
New approval expands market access and convenience, directly driving future sales.
Canada Recommends Public Reimbursement for Leqembi Canada's Drug Agency gave a final positive recommendation for public reimbursement of Leqembi. This paves the way for government-funded access, potentially increasing patient numbers and sales in Canada.
Reimbursement is crucial for uptake; this opens a new market for Eisai.
China and Japan Approve Subcutaneous Leqembi, Enabling At-Home Use China and Japan approved subcutaneous Leqembi, allowing at-home administration. This could significantly boost adoption by removing the need for hospital infusions, expanding the patient pool in two major markets.
Subcutaneous approval in key markets improves convenience and access, driving demand.
FDA Approves WELIREG Plus LENVIMA for Advanced Kidney Cancer The FDA approved the combination of WELIREG and Eisai's LENVIMA for advanced kidney cancer, based on a trial showing reduced progression risk. This adds a new revenue stream for Eisai's oncology portfolio.
New approval diversifies Eisai's revenue beyond Alzheimer's, supporting growth.

July 202630 Jun – 16 Jul 2026

▲4

FDA clears at-home Leqembi shot; real-world data and AI deal add momentum

FDA approves at-home Leqembi injection The FDA approved LEQEMBI IQLIK, a once-weekly under-the-skin injection, as a starting dose for early Alzheimer's. It is the first anti-amyloid therapy with at-home dosing from the start, launching in late August. Easier use could widen demand and lift 4523.JP.
This is the period's biggest new approval, directly expanding Leqembi's market and Eisai's revenue potential.
Real-world study backs Leqembi benefit A real-world LEADER study found 83% of early Alzheimer's patients on LEQEMBI stayed stable or improved over about 17 months. This independent evidence supports the drug's effectiveness, which can reassure doctors, patients and payers, supporting 4523.JP.
New real-world data strengthens the commercial case for Leqembi beyond clinical trials.
UK validates taletrectinib lung cancer filing Eisai's UK marketing application for taletrectinib in ROS1-positive lung cancer was validated by the MHRA, adding to an EU filing. Approval would expand Eisai's oncology sales in licensed territories, a smaller but real positive for 4523.JP.
New regulatory progress for a second Eisai drug diversifies growth beyond Alzheimer's.
Eisai joins Nvidia AI drug discovery push Eisai is deploying Nvidia's BioNeMo platform for AI-powered drug discovery, part of Nvidia's broad Japan AI partnerships. Faster, cheaper early research could improve Eisai's pipeline productivity over time, a modest but supportive signal for 4523.JP.
New AI partnership shows Eisai investing in research efficiency, a longer-term positive.

30 Jun – 16 Jul 2026

▲4

FDA clears at-home Leqembi shot; real-world data and AI deal add momentum

FDA approves at-home Leqembi injection The FDA approved LEQEMBI IQLIK, a once-weekly under-the-skin injection, as a starting dose for early Alzheimer's. It is the first anti-amyloid therapy with at-home dosing from the start, launching in late August. Easier use could widen demand and lift 4523.JP.
This is the period's biggest new approval, directly expanding Leqembi's market and Eisai's revenue potential.
Real-world study backs Leqembi benefit A real-world LEADER study found 83% of early Alzheimer's patients on LEQEMBI stayed stable or improved over about 17 months. This independent evidence supports the drug's effectiveness, which can reassure doctors, patients and payers, supporting 4523.JP.
New real-world data strengthens the commercial case for Leqembi beyond clinical trials.
UK validates taletrectinib lung cancer filing Eisai's UK marketing application for taletrectinib in ROS1-positive lung cancer was validated by the MHRA, adding to an EU filing. Approval would expand Eisai's oncology sales in licensed territories, a smaller but real positive for 4523.JP.
New regulatory progress for a second Eisai drug diversifies growth beyond Alzheimer's.
Eisai joins Nvidia AI drug discovery push Eisai is deploying Nvidia's BioNeMo platform for AI-powered drug discovery, part of Nvidia's broad Japan AI partnerships. Faster, cheaper early research could improve Eisai's pipeline productivity over time, a modest but supportive signal for 4523.JP.
New AI partnership shows Eisai investing in research efficiency, a longer-term positive.

Replimune Group Inc (REPL)

Q3 202623 Jun – 11 Aug 2026

▲2▼2

FDA panel backs RP1, approval and offering reshape Replimune

FDA panel backs RP1 An FDA advisory panel voted 10-3 that RP1's single-arm IGNYTE data were clinically meaningful, reversing earlier doubts and sending shares up over 130% premarket; Wedbush upgraded the stock.
This was the key regulatory catalyst that drove the stock's massive jump.
Accelerated approval of Tudriqev The FDA granted accelerated approval to Tudriqev plus Opdivo for advanced melanoma (24.2% response rate), giving Replimune its first commercial product and revenue stream.
This approval is a major milestone that transforms the company's business prospects.
Securities fraud investigations Two law firms (Kirby McInerney, Bragar Eagel & Squire) and later Pomerantz opened securities fraud investigations into whether the company misled investors before the FDA's critical July 28 briefing documents.
These investigations pose a legal overhang that could weigh on the stock.
Dilutive stock offering A $150 million stock offering at $12.06/share issued ~9.7 million new shares, diluting existing holders.
The offering dilutes current shareholders and can pressure the share price.

July 202623 Jun – 11 Aug 2026

▲2▼2

FDA panel backs RP1, approval and offering reshape Replimune

FDA panel backs RP1 An FDA advisory panel voted 10-3 that RP1's single-arm IGNYTE data were clinically meaningful, reversing earlier doubts and sending shares up over 130% premarket; Wedbush upgraded the stock.
This was the key regulatory catalyst that drove the stock's massive jump.
Accelerated approval of Tudriqev The FDA granted accelerated approval to Tudriqev plus Opdivo for advanced melanoma (24.2% response rate), giving Replimune its first commercial product and revenue stream.
This approval is a major milestone that transforms the company's business prospects.
Securities fraud investigations Two law firms (Kirby McInerney, Bragar Eagel & Squire) and later Pomerantz opened securities fraud investigations into whether the company misled investors before the FDA's critical July 28 briefing documents.
These investigations pose a legal overhang that could weigh on the stock.
Dilutive stock offering A $150 million stock offering at $12.06/share issued ~9.7 million new shares, diluting existing holders.
The offering dilutes current shareholders and can pressure the share price.

Latest23 Jun – 11 Aug 2026

▲2▼2

FDA approves Replimune's first drug, then company raises $150M

FDA grants accelerated approval for Tudriqev The FDA granted accelerated approval to Replimune's Tudriqev combined with Opdivo for advanced melanoma, based on a 24.2% response rate. This is the company's first commercial product, turning it from a clinical-stage hopeful into a revenue-generating business and lifting the stock.
This is the single biggest new event: approval validates the drug and opens a path to sales.
Securities fraud investigation expands to Pomerantz Pomerantz LLP opened an investigation into whether Replimune misled investors before the FDA's July 28 briefing documents questioned the RP1 data. This adds to earlier law firm probes, keeping a legal cloud over the stock and potentially weighing on the price.
It is a new law firm joining the investigation, adding fresh negative pressure.
$150 million stock offering dilutes shareholders Replimune priced a $150 million stock sale at $12.06 per share, issuing about 9.7 million new shares. This raises cash to launch Tudriqev but dilutes existing investors' ownership, which typically pushes the stock down in the short term.
It is a new financing event that directly affects share count and cash position.
FDA flexibility and biotech rally support Replimune The FDA signaled a more flexible approval approach for serious diseases, opening new pathways for Replimune and others. This supportive regulatory backdrop helped biotech stocks broadly and made RP1's eventual approval more likely, lifting sentiment around Replimune.
It explains the favorable regulatory environment that helped Replimune's path to approval.

30 Jul – 31 Jul 2026

▲2▼1

FDA panel backs RP1, reversing prior briefing-document collapse

FDA advisory panel votes 10-3 in favor of RP1 An FDA advisory committee voted 10 to 3 that RP1's single-arm IGNYTE study results are evaluable and clinically meaningful for advanced melanoma. This removes the main regulatory doubt and makes approval by the August 2 target date far more likely, pushing the stock sharply higher.
This is the core new event that flipped sentiment and drove the huge price jump.
Stock surges over 130% premarket, analyst upgrade Replimune shares soared more than 130% before the open and were up about 94-125% during the day after the panel vote. Wedbush upgraded the stock to outperform from neutral, a sign that professional investors now see the approval path as much clearer.
Shows the market's immediate, large positive reaction and a key analyst endorsement.
Securities fraud investigations launched Two law firms, Kirby McInerney and Bragar Eagel & Squire, opened investigations into whether Replimune misled investors before the FDA's July 28 briefing documents called the RP1 study non-interpretable. No lawsuit has been filed yet, but this legal cloud could weigh on the stock.
A real counterweight that could hurt the stock even after the positive panel vote.